The 6 references in paper P. Isaev A., P. Rumyantsev O., V. Polkin V., A. Ilyin A., D. Syomin Yu., T. Agababyan A., S. Vasilkov V., V. Medvedev S., П. Исаев А., П. Румянцев О., В. Полькин В., А. Ильин А., Д. Семин Ю., Т. Агабабян А., С. Васильков В., В. Медведев С. (2015) “КЛИНИЧЕСКИЕ СЛУЧАИ ЭФФЕКТИВНОСТИ НЕКСАВАРА (СОРАФЕНИБА) ПОСЛЕ ТЕРАПИИ 131I У БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ ДИФФЕРЕНЦИРОВАННЫМ РАКОМ ЩИТОВИДНОЙ ЖЕЛЕЗЫ // CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I” / spz:neicon:ogsh:y:2014:i:2:p:46-50

1
Sherman S. I. Target therapy of thyroid cancer. Biochem Pharmacol 2010 Sep;80(5):525–31.
(check this in PDF content)
2
Chougnet C., Brassard M., Leboulleux S. et al. Molecular targeted therapies for patient with refractory thyroid cancer. Clin Oncol (R Coll Radiol) 2010 Aug;22(6):448–55.
(check this in PDF content)
3
Licitra L., Locati L. D., Greco A. et al. Multikinase inhibitors in thyroid cancer. Eur J Cancer 2010 Apr;46(6): 1012–8.
(check this in PDF content)
4
Matuszczyk A., Petersenn S., Bockisch A. et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008 Mar;40(3):210–3.
(check this in PDF content)
5
Brose M. S., Nutting C. M., Jarzab B. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014 Apr 23. doi: 10.1016 / S0140–
(check this in PDF content)
6
36(14) 60421–9. 6. Keefe S. M., Cohen M. A., Brose M. S. Targeting vascular endothelial growth factors receptor in thyroid cancer: the intracellular and extracellular
(check this in PDF content)